82 results about "Normal lung" patented technology

The invention discloses polypeptide for specifically targeting a lung cancer cell and an application thereof. The polypeptide for specifically targeting the lung cancer cell has an amino acid sequence shown as SEQ ID NO.1, and is prepared by screening on the surface of the human lung cancer cell by an ex-vivo bacterial random polypeptide library exhibiting method and a flow cell sorting method. The polypeptide for specifically targeting the lung cancer cell can be applied to preparation of lung cancer diagnosing tracer, lung cancer cell detecting reagent and the like. The polypeptide for specifically targeting the lung cancer cell can be combined with a lung cancer A549 cell specifically, is not combined with a normal lung cell and other tumor cells; and the preparation method is simple, feasible and applicable to large-scale industrial production. The polypeptide for specifically targeting the lung cancer cell provides important theoretical and practical basis for early diagnosis, targeting therapy of the lung cancer and the like, and has a wide application prospect.

Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and / or proteins that are selectively expressed at a high or low level in certain tumor subtypes. Biomarker expression can be assessed at the protein or nucleic acid level.

Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and / or proteins that are selectively expressed at a high or low level in certain tumor subtypes. Biomarker expression can be assessed at the protein or nucleic acid level.

The invention discloses an HoxC11 gene or HoxC11 gene which can be used for preparing a lung adenocarcinoma pre-diagnostic reagent and a kit and preparing lung adenocarcinoma pre-diagnostic prognosis evaluation reagents or treatment drugs. Reverse transcription is performed after RNA is extracted from a normal lung tissue sample of lung adenocarcinoma, expression of HoxC11 is detected through a real-time fluorescence quantification method, and a result shows that HoxC11 can be highly expressed in lung adenocarcinoma tissue. It is promoted that HoxC11 can be used as a lung adenocarcinoma pre-diagnostic molecular marker. The powerful molecular biology tool is provided for lung adenocarcinoma auxiliary diagnosis and prognosis prediction, and the profound clinic significance and significant application and popularization prospects are achieved.

The invention discloses an application of a Lnc03729 gene c as a biomarker in the preparation of markers for diagnosis, prognosis evaluation and therapeutic guidance of lung adenocarcinoma. RNA is extracted from lung adenocarcinoma and normal lung tissue samples and is reversely transcribed, the expression of Lnc03729 is detected through a real-time fluorescent quantitative PCR technology, the expression of human lung adenocarcinoma cell Lnc03729 is exogenously up-regulated, and the change of the proliferation and the metastasis of the cells is detected through MTS and Transwell experiments. Aresult shows that the Lnc03729 is under-expressed in the lung adenocarcinoma tissues, and the up-regulation of the expression of the human lung adenocarcinoma cells Lnc03729 significantly down-regulates the proliferation and metastasis ability of the cells, so it is prompted that the Lnc03729 can be used as a marker for the malignancy and the patient prognosis evaluation of the lung adenocarcinoma cells. The application provides a powerful molecular biology tool for the auxiliary diagnosis, prognosis prediction and therapeutic guidance of the lung adenocarcinoma, and has far-reaching clinicalsignificance and important promotion and application prospects.

Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice. Overexpression of GLDC in non-tumorigenic subpopulation convert the cells to become tumorigenic. Furthermore, over-expression of GLDC in NIH / 3T3 cells and human primary lung fibroblasts can transform these cells, displaying anchorage-independent growth in soft agar and tumor-forming in mice. Not only is GLDC is expressed human lung cancer, it is also up-regulated in other types of cancer, such as colon cancer. RNAi knockdown of GLDC in colon cancer cell line, CACO-2 cells, can also inhibit the tumor formation in mice. Thus GLDC maybe a new metabolic target for treatment of lung cancer, and other cancers.

The invention discloses application of a compound to preparation of a medicament for treating the acute lung injury. The compound disclosed by the invention can effectively reduce a death rate causedby the acute lung injury and recover the normal lung function, and a treatment effect of the compound is equivalent to that of dexamethasone acetate; and in addition, the compound can be orally taken,is more convenient to use and has important medical prospect and economic value.

The invention relates to the technical field of biomedicine engineering and provides application of a reagent for inhibiting or down-regulating expression of a GTSE1 gene in preparation of a tumor radiotherapy sensitization drug, particularly application in preparation of a lung cancer radiotherapy sensitization drug. Experiments prove that GTSE1 knockdown promotes DNA damage of exposure to lung cancer cells, increases the radiosensitivity of three lung censer cells significantly and increases the apoptosis rate of the three lung cancer cells after exposure significantly with the increase of an exposure dose, and the cell survival rate of the three lung cancer cells is obviously lower than that of a normal lung cancer cell group. Therefore, the application provides a new exploration for improving the sensitivity of radiotherapy, contributes to radiotherapy sensitivity of malignant tumor and has certain clinical application prospects.

The invention relates to the field of lung cancer treatment, in particular to genetic biomarkers for predicting or assisting in predicting the risk of radiation pneumonitis after pulmonary radiation,and application of the genetic biomarkers. The genetic biomarkers comprise single-nucleotide polymorphic sites from RP2-01 to RP2-31; and the group of the genetic biomarkers fills in the absence of abiomarker which can be used for predicting the risk of radiation pneumonitis after the pulmonary radiation in patients in the prior art. The group of the single-nucleotide polymorphic sites is of different genotypes in different individuals; the different genotypes can affect the sensitivity of normal lung tissues to radiation; by detecting and evaluating the sites, a prognosis can be assisted; and the genetic biomarkers are of great significance to guide the monitoring and treatment of patients with a lung cancer after radiotherapy.

The invention discloses lung adenocarcinoma biomarkers and related application, and the biomarkers are at least two of S100P, COL17A1, CXCL14 and GLB1L3. The study of the present invention demonstrates that the mRNA expression levels of S100P, COL17A1, CXCL14 and GLB1L3 genes are significantly up-regulated in lung adenocarcinoma patients compared with normal lung tissues. ROC curve analysis showsthat the combination of the above genes has a high AUC value, suggesting that S100P, COL17A1, CXCL14 and GLB1L3 can be combined and applied for the diagnosis of lung adenocarcinoma, and can be used toprepare products for the diagnosis of lung adenocarcinoma, and the products can be used in clinical application.

The invention discloses a method for culturing human normal lung tissue and lung cancer tissue organoids in vitro, comprising obtaining fresh human lung tissue cells and digesting them into single cells with collagenase; cultivating human lung tissue and lung cancer tissue organoids under 3D culture conditions in vitro . The method of culturing human normal lung tissue and lung cancer tissue organoids in vitro: obtain fresh human lung tissue cells, digest them into single cells with collagenase; cultivate human lung cancer tissue organoids under 3D culture conditions in vitro; H&E staining to clarify the structure and morphology , q-PCR detection of related gene expression; immunofluorescence staining to identify cell source detection of related protein expression. And the method of constructing mouse animal models based on the above-mentioned organoids is of great significance for the construction of large-scale and consistent human-derived and orthotopic lung cancer animal models, providing a good foundation for basic research on lung cancer and related clinical applications prospect.

The invention discloses a 1-(2,6-chlorphenyl)-3-substituted urea compound capable of acting on colon cancer, a preparation method and applications thereof. According to the present invention, the 1-(2, 6-dichlorophenyl)-3-(6-(substituted benzylamino)pyrimidine-4-yl) urea compound does not have toxic effect on the proliferation of BEAS-2B cells (normal lung cells), and has a certain inhibitory effect on three selected colon cancer cell lines including SW116 cells (human large intestine cancer cells), SW480 cells (human colon cancer cells) and SW620 cells (human colon cancer cells) so as to provide a certain antitumor activity.

The invention discloses a lung cancer tissue separator, and the separator comprises a table top, a transverse moving device, a separating device, a clamping device, a portal frame and an opening device; when a lung cancer tissue separation operation is carried out, a patient needs to lie on the table top, then the portal frame moves to the position over the part, needing the operation, of the patient, and then the separating device is driven to move downwards to a proper position; the distraction device is used for distraction of a surgical incision of a patient and guaranteeing a surgical space, the clamping device located over clamps a focus, the separation device rotates by 180 degrees to cut off a membrane on the outer side of a pulmonary lobe, then the clamping device located on the side clamps pulmonary lobe tissue below the incision, the clamping device located above moves upwards, blunt separation of cancer tissue and normal lung tissue is achieved, blood vessels are exposed, separation of the cancer tissue is completed after the blood vessels are sutured, and the device has the advantages of being high in automation degree, convenient to operate, safe and reliable.

The invention belongs to the technical field of biomedical testing, and particularly relates to a tRNA related lung adenocarcinoma prognosis model and application of the tRNA related lung adenocarcinoma prognosis model, the tRNA related lung adenocarcinoma prognosis model and the application of the tRNA related lung adenocarcinoma prognosis model comprise providing the application of detecting theexpression level of tRNA in a tissue to the prognosis of the adenocarcinoma of lung, the application is finished through the following steps: step 1, quantifying the tRNA of the adenocarcinoma of lung and the normal lung tissue; step 2, establishing correlation between tRNA and the adenocarcinoma of lung; and step 3, establishing a tRNA related prognosis scoring model. 50 pairs of adenocarcinomaof lung and the corresponding tumor adjacent tissue are screened through a qPCR (Polymerase Chain Reaction) chip, and the quantitative expression condition of the tRNA of the corresponding tissue is disclosed. The invention aims at screening a specific tRNA molecule related to the prognosis of a patient suffering from the adenocarcinoma of lung, and provides the tRNA prognosis model for diagnosingand treating the adenocarcinoma of lung; another purpose of the invention is to provide the application of the specific tRNA combination to the preparation of a kit for predicating the prognosis of the adenocarcinoma of lung, and the invention provides the application of the prognosis model to the prognosis of the adenocarcinoma of lung and a related kit to the diagnosis and the prognosis of theadenocarcinoma of lung.